Skip to main content
Fig. 2 | Infectious Agents and Cancer

Fig. 2

From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine

Fig. 2

Construction of a mouse cervical cancer U14 cell line stably expressing the HPV16/18/58 E6E7 fusion protein. A Fluorescence microscopy was used to detect the expression of green fluorescent protein in the U14/LV-HPV18 E6E7 cells and U14/LV-NC cells. B Fluorescence microscopy was used to detect the expression of green fluorescent protein in the U14/LV-HPV58 E6E7 cells and the U14/LV-NC cells. C The expression of the HPV16 E6 and HPV16 E7 genes was detected in TC-1 cells by RT-PCR (HPV E6 249 bp, HPV E7 199 bp). D The expression of the HPV18 E6E7 fusion gene in each group was detected by RT-PCR. M: DNA ladder (100 bp) A: U14/LV-HPV18 E6E7 group (HPV18 E6E7 789 bp), B: U14/LV-NC group, C: U14 group. E The expression of the HPV58 E6E7 fusion gene in each group was detected by RT-PCR M: DNA marker (50 bp) a: U14/LV-HPV58 E6E7 group (HPV58 E6E7 741 bp), b: U14/LV-NC group, c: U14 group. F Western blot analysis showed that the HPV16 E6 and E7 proteins in TC-1 cells can be expressed. G Western blot analysis showed that the HPV18 E6E7 protein in the U14/LV-HPV18 E6E7 cells could be detected. A: U14/LV-HPV18 E6E7 group, B: U14/LV-NC group C: U14 group, a: anti-E6 protein, b: anti-E7 protein. H Western blot analysis confirmed that the U14/LV-HPV58 E6E7 fusion protein was expressed in cells from the A: U14/LV-HPV58 E6E7 group, B: U14/LV-NC group, and C: U14 group

Back to article page